Macartney Welborn, MD

BOARD-CERTIFIED DERMATOLOGIST AND DERMATOPATHOLOGIST
Dr. Macartney Welborn

Dr. Macartney Welborn is a board-certified dermatologist and dermatopathologist with the American Board of Dermatology. She completed her undergraduate studies at Southern Methodist University, graduating Summa Cum Laude with a double major in Biology and Chemistry. Dr. Welborn earned her medical degree and completed her internship at the University of Texas Health Science Center at Houston. She then pursued her dermatology residency at the University of Florida where she served as Chief Resident from 2022-2023, and further specialized in dermatopathology through a fellowship also at the University of Florida.

Dr. Welborn has extensive research experience, with contributions to numerous journal publications, book chapters, abstracts, and presentations. Her peers have recognized her commitment to patient care and excellence in practice by electing her twice to the Gold Humanism Honor Society as a medical student and again as a resident physician. Throughout her training, she has held significant roles, including participation in the Dialogues in Dermatology Podcast and directing the University of Florida Equal Access Clinic for uninsured patients.

Dr. Welborn’s practice philosophy emphasizes the importance of effective communication with providers and the integration of clinical and pathological findings to ensure accurate diagnoses and optimal patient care. Her dedication to advancing dermatologic medicine through research and community service underscores her value as a member of the Sagis team.

Education

Fellowship Training

Dermatopathology
University of Florida | Dermatology Department
Gainesville, FL

Residency Training

Dermatology
University of Florida | Dermatology Department
Gainesville, FL

Medical School

McGovern Medical School at UTHealth
Houston, TX

Undergraduate

Southern Methodist University
Dallas, TX

Board Certifications

Dermatology

American Board of Dermatology

Dermatopathology

American Board of Dermatology

Memberships

Research & Publications

Dr. Macartney Welborn’s research studies and publication work is extensive and quite impressive. Publication categories include textbook chapters, medical research, and various clinical publications.

Publications
  • Welborn M, Kubicki SL, Garg N, Patel AB. Retrospective chart review of cutaneous adverse events associated with tremelimumab in 17 patients. Am J Clin Dermatol. 2018;19(6):899-905.
  • Kubicki SL, Welborn M, Garg N, Aung PP, Patel AB. Granulomatous dermatitis associated with ipilimumab therapy (Ipilimumab associated granulomatous dermatitis). J Cutan Pathol. 2018;45(8):636-638.
  • Welborn M, Kubicki S, Patel A. Pyoderma gangrenosum following initiation of immune checkpoint inhibitor therapy. J Immunother Precis Oncol. 2018;1(2):82.
  • Kubicki S, Welborn M, Patel A. Toxic epidermal necrolysis during cotherapy with ipilimumab and nivolumab. J Immunother Precis Oncol. 2018;1(2):78.
  • Welborn M, Duvic M. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma. Am J Clin Dermatol. 2019;20(1):115-122.
  • Welborn M, Dallo C, Altmeyer M. Cutis verticis gyrata improved with injected hyaluronidase treatments. Dermatol Arch. 2019;3(1).
  • Welborn M, Kubicki SL, Garg N, Patel AB. Twelve cases of acneiform eruptions while on anti-CTLA4 therapy. Support Care Cancer. 2020;28(6):2499-2502.
  • Dallo C, Welborn M, Altmeyer M. A case of multiple hereditary infundibulocystic basal cell carcinoma syndrome. Int J Dermatol. 2020;59(10):e383-e384.
  • Dutra B, Welborn M, Thosani NC, Badillo R, DaVee T, Bhakta D. Endoscopic coil embolization for refractory intrahepatic biliary duct leak. ACG Case Rep J. 2022;9(2):e00743.
  • Raman J, Braunlich K, Welborn M, Hooey L, Motaparthi K. Cytomegalovirus infection presenting as an isolated petechial eruption in an immunocompromised patient. JAAD Case Rep. 2022;20:6-9.
  • Welborn M, Fletcher D, Motaparthi K. Atrophy of sebaceous lobules in facial discoid dermatosis: a link to psoriasis and seborrheic dermatitis? J Cutan Pathol. 2022;49(3):320-323.
  • Patel AB, Farooq S, Welborn M, et al. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer. 2022;128(5):975-983.
  • Marion T, Welborn M, Della Porta A, Schoch J, Konda S. Publication productivity using h-index to evaluate academic success among fellowship-trained mohs surgeons. Dermatol Surg. 2023;49(1):25-28.
  • Smith KN, Welborn M, Monir RL, Motaparthi K, Schoch JJ. Pediatric pyoderma gangrenosum associated with leukocyte adhesion deficiency type 1: A case report and review of the literature. Pediatr Dermatol. Published online March 31, 2023.
  • Malik AM, Welborn M, Gao H, Motaparthi K. Self-directed virtual educational strategies for dermatopathology: A prospective comparison of Instagram-based static images to whole slide images. J Cutan Pathol. Published online June 4, 2023.
Book Chapters
  • Raman J, Welborn M, Motaparthi K. Bubble Hair. Diagnostic Pathology: Nonneoplastic Dermatopathology. 2022; Third Ed: 430-431
  • Raman J, Welborn M, Motaparthi K. Pili Annulati. Diagnostic Pathology: Nonneoplastic Dermatopathology. 2022; Third Ed: 434-435
  • Raman J, Welborn M, Motaparthi K. Lice/Nit. Diagnostic Pathology: Nonneoplastic Dermatopathology. 2022; Third Ed: 438-439
  • Raman J, Welborn M, Motaparthi K. Hair Cast. Diagnostic Pathology: Nonneoplastic Dermatopathology. 2022; Third Ed: 440-441
  • Cox E, Welborn M, Saikaly SK, Motaparthi K. Checkpoint Inhibitor Reactions. Diagnostic Pathology: Nonneoplastic Dermatopathology. 2022; Third Ed: 446-449
  • Perche P, Welborn M, Motaparthi K. Keratoderma. Diagnostic Pathology: Nonneoplastic Dermatopathology. 2022; Third Ed: 476-477
Reports
Abstracts
  • Welborn M, Kubicki SL, Patel AB. Cutaneous Adverse Events in tremelimumab, a 2nd generation anti-CTLA4 inhibitor. Poster session presented at the 75th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 2017.
  • Kubicki SL, Welborn M, Patel AB. Granulomatous dermatitis induced by ipilimumab. Poster session at the Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 2017
  • Niekamp, A, Cardenas N, Goldberg J, Welborn M, Celii F, Bhatti, Z, Guevara, C, Pillai A. Utility of imaging criterion in lower LI-RADS categories as a prognostic tool for preemptive treatment prior to progression to hepatocellular cancer. Oral presentation at the Annual Meeting of the Society of Interventional Radiology, Los Angeles, CA, March 2018.
  • Patel AB, Farooq S, Welborn M, Haydu LE. 14052 Cutaneous toxicities in combination immune checkpoint inhibitor therapy for metastatic melanoma: Impact on therapy course. Journal of the American Academy of Dermatology. 2020;83(6):AB17.
Poster Presentations
  • Welborn M, Andrews, T, Aune, G. Quantification of Collage Using Picrosirius Red Staining. Poster session presented at the Greehey Children’s Cancer Research Institute, San Antonio, TX, August 2012.
  • Ruh N., Welborn M., Kingry C., Son D. Thiol Michael Reactions of Alkynes. Poster session presented at the 247th Annual Meeting of the American Chemical Society, Dallas, TX, March 2014.
  • Welborn M, Kubicki SL, Patel AB. Cutaneous Adverse Events in tremelimumab, a 2nd generation anti-CTLA4 inhibitor. Poster session presented at the 75th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 2017.
  • Kubicki SL, Welborn M, Patel AB. Granulomatous dermatitis induced by ipilimumab. Poster session at the Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 2017.
  • Pye A, Welborn M, Lopez-Pineiro M, Jahan-Tigh R. Levamisole-induced vasculitis/vasculopathy in the setting of chronic systemic lupus erythematosus. Poster session at the Texas Dermatological Society Annual Spring Meeting, Austin, TX, April 2018.
  • Kubicki SL, Welborn M, Patel AB. Cutaneous adverse events induced by poziotinib therapy. Poster session at the Texas Dermatological Society Annual Spring Meeting, Austin, TX, April 2018.
  • Welborn M, Reid H, Hymes S. Chronic GVHD Presenting as Blaschkoid Lichen Planus Pigmentosus. Poster session at the Texas Dermatological Society Annual Spring Meeting, Galveston, TX, September 2018.
  • Farooq S, Welborn M, Haydu L, Patel AB. Management and Outcomes of Cutaneous Adverse Events in Combination Immune Checkpoint Therapy. Poster session at the Texas Dermatological Society Annual Spring Meeting, Galveston, TX, September 2018.
  • Welborn M, Purvis C, Dhaliwal P, Motaparthi K; Columnar dyskeratosis in hydroxyurea-induced dermatomyositis. Poster session at the American Society of Dermatopathology, Chicago, IL, October 2023.
  • Welborn M, Perelygina L, Faisthalab R, Wanat K MD; Histopathologic features of granulomatous disease associated with Rubella Virus. Poster session at the American Society of Dermatopathology, Chicago, IL, October 2023.
Oral Presentations
  • Welborn M, Taing M, Lytle K. Whole Exome Sequencing in Rare Neurologic Disorders. Presented at Pediatric Neurology Grand Rounds, Houston, TX, December 2017.
  • Welborn M, Son D. Synthesis of Hydrogenated Thiol-Silanes. Presented at Engaged Learning Summit,
    Dallas, TX, December 2014.